NRx's Half -Yearly Loss Narrows; ANDA Response For NRX-100 In '27

NRx Pharmaceuticals Inc. (NRXP), a clinical-stage biopharmaceutical company, on Monday announced financial results for the first half year and second quarter of 2026, noting a lower net loss owing to certain air-value accounting measures and a convertible notes conversion.